PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
about
Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast CancerMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerMEK and PI3K inhibition in solid tumors: rationale and evidence to datePI3K and AKT: Unfaithful Partners in CancerCancer cells exploit adaptive mitochondrial dynamics to increase tumor cell invasionTen things you should know about protein kinases: IUPHAR Review 14The dynamic nature of the kinomePosttranslational regulation of Akt in human cancerLung cancer cells that survive ionizing radiation show increased integrin α2β1- and EGFR-dependent invasivenessCo-Targeting of JNK and HUNK in Resistant HER2-Positive Breast CancerActivation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung CancerMet receptor acts uniquely for survival and morphogenesis of EGFR-dependent normal mammary epithelial and cancer cellsArsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancerGene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to TherapyTargeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?The phosphoinositide 3-kinase pathway and therapy resistance in cancerDiscovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitorHER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1BPten loss promotes MAPK pathway dependency in HER2/neu breast carcinomasp70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanismsActive kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitorsWhere now for anti-EGF receptor therapies in colorectal cancer?Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathwaysTherapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancerIn-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways.Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.Epidermal Growth Factor Receptor Cell Proliferation Signaling PathwaysRational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathwayEffective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways.Current Approaches and Emerging Directions in HER2-resistant Breast Cancer.The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivitySrc, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.
P2860
Q26753162-164A0AD6-051F-4597-A13D-1D4892915004Q26772969-CBFBDC59-E274-4228-B710-2FCC03B7ACE5Q26775573-BA91499E-3E29-40E3-9A96-B894D7701A74Q26781367-3926FE7E-D9F2-40EA-8DBA-E02230C64629Q26796364-FBE03276-9CD3-49E4-B487-989CFC2205DFQ26849417-4B43C61D-6BBD-426B-983F-AC38BA59FD66Q26852588-9684CB86-A007-4D9E-BF93-6A4DEA2FA809Q27027815-C9B2197F-6190-4145-A65B-7FE5594BFB08Q27310015-92FA4E62-9975-44AB-9FF0-8946601A8385Q27314840-7CB185BA-FE26-4103-A693-24CE0364921CQ27315948-28C279D5-A7E6-4381-AD40-205B81DD3101Q27318931-A8948FA6-EBF6-4CB8-BF34-ECF1AFE95746Q27332151-02ED364C-D28F-4739-8DA7-5FC3A68A1FCEQ27853108-00AF302F-44F5-48C3-81C9-3CEC278172D1Q28070028-0DA206BC-D2A6-4E35-98F0-9B1F0D4CFB1EQ28079596-AB84E9DA-5A51-4BBD-8EB1-9BECCB7AEEEDQ28082811-6BB6BB34-1A0B-49B0-9CCC-E4A909DDA6B9Q28540161-9DB4D94F-C5D2-4DBE-A159-EF4818FC771DQ28551145-DED9C163-F844-4547-9173-03E06A5797A8Q28602310-B2BF94A6-A0BF-4AE1-A98D-A898B6D61FAAQ30371561-AFA3383A-973E-4F0C-9CD7-E8CADBE83C9AQ30418057-A37DADAB-A221-496F-B473-DC7645E37F91Q30582030-7C9E1B19-A30F-44F8-8BF7-DF94D979C7B8Q30620482-B31529F4-AA3B-4A0A-8939-D41A59138041Q31038305-CB1CD0AF-4423-48D7-BB5F-6321B368C1ECQ33584432-FAF2AD62-9EC9-43DA-AFEF-E67F83D4573FQ33591690-EF37AD71-ED11-419C-9DC9-B352F952E2B9Q33601377-6DF7C672-5E07-46A6-A3AD-A21ECFA76D16Q33607950-12058630-4672-494A-A20C-7601CFFEA76AQ33687272-DD5F4D9F-CCF4-4A30-BFBA-096B29047F1AQ33726847-A8FA342B-FB72-4392-BDEF-D8D654BD961AQ33737298-38116BA5-EF60-406A-87BD-8F2B8B4529C0Q33840360-74AEB2F1-A8ED-4E56-9313-BE8AE9F03F85Q33842810-7B02D37A-1091-487A-B63D-D0AF109FE9B6Q33864477-AF3A5C48-516C-4E22-821B-4B89551A6A92Q33934922-BDF4003D-1AA7-4AC9-B764-5AB85BA78AF3Q34016480-BB618380-DC21-480E-A006-BA4359114CF7Q34036041-ED62F8D0-4004-45C3-B03D-93695BD090A3Q34051933-8DA72562-291E-4894-A444-4CBB74840674Q34135475-9A4107F1-EBBE-45CD-92A7-14FC62219EB6
P2860
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
PI3K inhibition results in enh ...... 2-overexpressing breast cancer
@ast
PI3K inhibition results in enh ...... 2-overexpressing breast cancer
@en
PI3K inhibition results in enh ...... 2-overexpressing breast cancer
@en-gb
PI3K inhibition results in enh ...... 2-overexpressing breast cancer
@nl
type
label
PI3K inhibition results in enh ...... 2-overexpressing breast cancer
@ast
PI3K inhibition results in enh ...... 2-overexpressing breast cancer
@en
PI3K inhibition results in enh ...... 2-overexpressing breast cancer
@en-gb
PI3K inhibition results in enh ...... 2-overexpressing breast cancer
@nl
prefLabel
PI3K inhibition results in enh ...... 2-overexpressing breast cancer
@ast
PI3K inhibition results in enh ...... 2-overexpressing breast cancer
@en
PI3K inhibition results in enh ...... 2-overexpressing breast cancer
@en-gb
PI3K inhibition results in enh ...... 2-overexpressing breast cancer
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
PI3K inhibition results in enh ...... 2-overexpressing breast cancer
@en
P2093
M Russillo
M Scaltriti
O Rodriguez
P2860
P2888
P304
P3181
P356
10.1038/ONC.2010.626
P407
P577
2011-06-02T00:00:00Z
P5875
P6179
1006324258